The SIGA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SIGA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The SIGA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View SIGA Detailed Price Forecast - CNN Money||View SIGA Detailed Summary - Google Finance|
|View SIGA Detailed Summary - Yahoo! Finance||View SIGA Stock Research & Analysis - Zacks.com|
|View SIGA Trends & Analysis - Trade-Ideas||View SIGA Major Holders - Barrons|
|View SIGA Call Transcripts - NASDAQ||View SIGA Breaking News & Analysis - Seeking Alpha|
|View SIGA Annual Report - CompanySpotlight.com||View SIGA OTC Short Report - OTCShortReport.com|
|View SIGA Fundamentals - TradeKing||View SIGA SEC Filings - Bar Chart|
|View Historical Prices for SIGA - The WSJ||View Performance/Total Return for SIGA - Morningstar|
|View the Analyst Estimates for SIGA - MarketWatch||View the Earnings History for SIGA - CNBC|
|View the SIGA Earnings - StockMarketWatch||View SIGA Buy or Sell Recommendations - MacroAxis|
|View the SIGA Bullish Patterns - American Bulls||View SIGA Short Pain Metrics - ShortPainBot.com|
|View SIGA Stock Mentions - StockTwits||View SIGA Stock Mentions - PennyStockTweets|
|View SIGA Stock Mentions - Twitter||View SIGA Investment Forum News - Investor Hub|
|View SIGA Stock Mentions - Yahoo! Message Board||View SIGA Stock Mentions - Seeking Alpha|
|View Insider Transactions for SIGA - SECform4.com||View Insider Transactions for SIGA - Insider Cow|
|View SIGA Major Holdings Summary - CNBC||View Insider Disclosure for SIGA - OTC Markets|
|View Insider Transactions for SIGA - Yahoo! Finance||View Institutional Holdings for SIGA - NASDAQ|
|View SIGA Stock Insight & Charts - FinViz.com||View SIGA Investment Charts - StockCharts.com|
|View SIGA Stock Overview & Charts - BarChart||View SIGA User Generated Charts - Trading View|
Siga Continues Rally After FDA Approves Smallpox Drug
Posted on Monday July 16, 2018
Siga Technologies (NASDAQ: SIGA) announced the FDA's approval of TPOXX, or tecovirimat. The drug consists of an antiviral treatment designed to diminish the effects of smallpox upon outbreak and is the first approved treatment of its kind. The smallpox drug's importance is twofold.
U.S. Food and Drug Administration Approves SIGA Technologies’ TPOXX® (tecovirimat) for the Treatment of Smallpox
Posted on Friday July 13, 2018
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) has approved oral TPOXX® (tecovirimat) for the treatment of smallpox to mitigate the impact of a potential outbreak. TPOXX, a small-molecule antiviral treatment for smallpox, is the first therapy specifically approved for this indication.
SIGA Technologies shares rise 10% on approval of first-ever smallpox therapy
Posted on Friday July 13, 2018
SIGA Technologies Inc. (SIGA) rose 9.6% in Friday afternoon trade on the Food and Drug Administration's approval of its TPOXX, the first-ever smallpox therapy. The contagious and often-deadly disease -- described as "one of the world's most devastating diseases known to humanity" by the World Health Organization -- has been considered eradicated since 1980 due to global immunization, but there have been fears that it could be used for bioterrorism, the FDA said. To establish the product's safety, it was tested in 359 healthy humans who did not have smallpox, while the efficacy findings that the approval was based on were in animals.
Pivotal Trial Data for SIGA Technologies’ Oral TPOXX® Published in the New England Journal of Medicine
Posted on Thursday July 05, 2018
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, which comprises countermeasures for biological, chemical, radiological and nuclear attacks as well as vaccines and therapies for emerging infectious diseases and health preparedness to address serious unmet medical needs, today announced the publication of data in the New England Journal of Medicine from its pivotal human safety and animal efficacy studies of its oral formulation of TPOXX® (tecovirimat). These results support the antiviral activity and favorable safety profile of TPOXX for the treatment of smallpox. “Smallpox is both highly contagious and highly lethal and there is growing concern that smallpox could be used as a potential bioweapon,” said Phil Gomez, PhD, SIGA’s Chief Executive Officer.